Processing

Please wait...

Settings

Settings

Goto Application

1. WO2019159193 - NOVEL HUMANIZED ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR, ITS NUCELIC ACID SEQUENCE AND ITS PREPARATION

Publication Number WO/2019/159193
Publication Date 22.08.2019
International Application No. PCT/IN2019/050111
International Filing Date 12.02.2019
IPC
C07K 16/28 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
A61K 39/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
CPC
A61K 2039/5156
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
51comprising whole cells, viruses or DNA/RNA
515Animal cells
5156expressing foreign proteins
A61K 2039/5158
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
51comprising whole cells, viruses or DNA/RNA
515Animal cells
5158Antigen-pulsed cells, e.g. T-cells
A61K 35/17
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
14Blood; Artificial blood
17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
A61K 39/001112
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
0005Vertebrate antigens
0011Cancer antigens
001102Receptors, cell surface antigens or cell surface determinants
001111Immunoglobulin superfamily
001112CD19, B4
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
C07K 14/7051
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
705Receptors; Cell surface antigens; Cell surface determinants
70503Immunoglobulin superfamily
7051T-cell receptor (TcR)-CD3 complex
Applicants
  • INDIAN INSTITUTE OF TECHNOLOGY BOMBAY [IN]/[IN]
Inventors
  • PURWAR, Rahul
  • DWIVEDI, Alka
  • KARULKAR, Atharva
  • SRINIVASAN, Srisathya
Agents
  • N, Shakira
Priority Data
20182100545813.02.2018IN
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) NOVEL HUMANIZED ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR, ITS NUCELIC ACID SEQUENCE AND ITS PREPARATION
(FR) NOUVEAU RÉCEPTEUR ANTIGÉNIQUE CHIMÉRIQUE ANTI-CD19 HUMANISÉ, SÉQUENCE D'ACIDE NUCLÉIQUE ASSOCIÉE ET PRÉPARATION CORRESPONDANTE
Abstract
(EN) The present invention relates to novel humanized anti-CD19chimeric antigen receptor containing an optimized anti-CD19 binding domain effective against the treatment of disease associated with expression of the Cluster of Differentiation 19 protein (CD19), and to a nucleic acid molecule encoding the humanized CAR. The invention also encompasses a process for the preparation of the CAR, composition containing the CAR, vectors containing the polynucleotide encoding the CAR and cells expressing the CAR at their surface, in particular for their use in immunotherapy.
(FR) La présente invention concerne un nouveau récepteur antigénique chimérique anti-CD19 humanisé contenant un domaine de liaison anti-CD19 optimisé efficace pour le traitement d'une maladie associée à l'expression de la protéine du groupe de différenciation 19 (CD19) et une molécule d'acide nucléique codant pour le CAR humanisé. L'invention concerne également un procédé de préparation du CAR, une composition contenant le CAR, des vecteurs contenant le polynucléotide codant pour le CAR et des cellules exprimant le CAR sur leur surface, en particulier pour leur utilisation en immunothérapie.
Related patent documents
Latest bibliographic data on file with the International Bureau